Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712737 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
CD ROMAdd to Basket
Electronic (PDF)Add to Basket
Site LicenseAdd to Basket
Live Chat Live Help Software for Website

Target Analytical Report - ABL1

Jubilant Biosys Limited, Sep 2008, Pages: 158


  Description  
   Table of Contents   
   Summary   
   Companies Mentioned   
    
     
  Enquire before Buying   
  Send to a Friend   

ABL1 (Abelson murine leukemia viral oncogene homolog 1; c-ABL) belongs to the SRC tyrosine kinase family. ABL1 is involved in many molecular signaling pathways, and plays a role in various cellular processes such as differentiation, DNA repair, stress response, cell division and actin reorganization.

Oncogenic forms of the protein, such as the fusion products BCR-ABL and TEL-ABL, as well as activating mutations in the ABL gene, have been associated with malignant transformation, such as in chronic myelogenous leukemia and a subset of acute lymphoblastic leukemia.

Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors. The malignant potential of this oncoprotein, the drug-resistant mutations and its ability to affect multiple signaling cascades, makes it a desirable therapeutic target.

Today, the drug discovery research sector faces tremendous internal and external pressure due to the huge investments required in terms of money and time in order to produce meaningful information from the huge data sources available in a molecule. This process involves the increased involvement of cross functional domains like those of Molecular Biology, Bioinformatics and Medicinal Chemistry, which has made the process cumbersome and complicated.

The current report on ABL1 addresses the above problem: this report is a compilation of manually curated information that is derived from;

- Public domain databases such as SwissProt, UniProt, Entrez PubMed, OMIM, etc
- In-house databases
- Curated information from journal articles and reviews
- Chemistry information from patents
- Company websites

Competitive Landscape:

The competitive landscape information is obtained by analysis of manually selected patents in the area of small molecules acting on the target.



Customers who bought this item also bought

Proteomics - Technologies, Markets and Companies

Target Analytical Report - CCKBR

G-Protein Coupled Receptors (GPCRs) - Global Strategic Business Report

Nanobiotechnology Applications, Markets and Companies

Biomarkers - Technologies, Markets and Companies

Cytogenetics - Technologies, Markets and Companies

DNA Sequencing - Technologies, Markets and Companies

RNAi - Technologies, Markets and Companies

Gene Therapy - Technologies, Markets and Companies

Innovations in Bioinformatics: Emerging Tools for Drug Discovery and Development



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds